Regenxbio Inc (RGNX)
9.59
+0.41
(+4.47%)
USD |
NASDAQ |
Nov 22, 16:00
9.60
+0.01
(+0.10%)
After-Hours: 20:00
Regenxbio Free Cash Flow: -184.74M for Sept. 30, 2024
Free Cash Flow Chart
Historical Free Cash Flow Data
| Date | Value |
|---|---|
| September 30, 2024 | -184.74M |
| June 30, 2024 | -194.72M |
| March 31, 2024 | -198.64M |
| December 31, 2023 | -228.37M |
| September 30, 2023 | -231.32M |
| June 30, 2023 | -235.98M |
| March 31, 2023 | -257.07M |
| December 31, 2022 | -238.21M |
| September 30, 2022 | 133.51M |
| June 30, 2022 | 127.82M |
| March 31, 2022 | 142.89M |
| December 31, 2021 | 134.70M |
| September 30, 2021 | -165.60M |
| June 30, 2021 | -146.94M |
| March 31, 2021 | -115.80M |
| December 31, 2020 | -80.93M |
| September 30, 2020 | -134.05M |
| June 30, 2020 | -123.35M |
| Date | Value |
|---|---|
| March 31, 2020 | -127.88M |
| December 31, 2019 | -119.42M |
| September 30, 2019 | -101.92M |
| June 30, 2019 | -93.01M |
| March 31, 2019 | 3.828M |
| December 31, 2018 | 91.37M |
| September 30, 2018 | 84.47M |
| June 30, 2018 | 89.82M |
| March 31, 2018 | 11.05M |
| December 31, 2017 | -65.15M |
| September 30, 2017 | -74.08M |
| June 30, 2017 | -70.54M |
| March 31, 2017 | -68.81M |
| December 31, 2016 | -56.71M |
| September 30, 2016 | -36.42M |
| June 30, 2016 | -30.85M |
| March 31, 2016 | -29.56M |
| December 31, 2015 | -23.04M |
Free Cash Flow Range, Past 5 Years
-257.07M
Minimum
Mar 2023
142.89M
Maximum
Mar 2022
-112.20M
Average
-140.49M
Median
Free Cash Flow Benchmarks
| Catalyst Pharmaceuticals Inc | 221.79M |
| EyePoint Pharmaceuticals Inc | -118.04M |
| Cassava Sciences Inc | -78.07M |
| Vertex Pharmaceuticals Inc | -1.352B |
| Sarepta Therapeutics Inc | -480.40M |
Free Cash Flow Related Metrics
| Cash from Operations (Quarterly) | -40.55M |
| Cash from Investing (Quarterly) | 50.26M |
| Cash from Financing (Quarterly) | -10.86M |
| Free Cash Flow Per Share (Quarterly) | -0.8046 |
| Free Cash Flow to Equity (Quarterly) | -40.88M |
| Free Cash Flow Yield | -40.31% |